NASDAQ:VERUVeru Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Veru Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.33 +0.08 (+2.46 %) (As of 04/10/2020 06:00 AM ET) Add Compare Share Today's Range$3.23Now: $3.33▼$3.4850-Day Range$2.58MA: $3.49▼$4.5852-Week Range$1.18Now: $3.33▼$4.74Volume216,074 shsAverage Volume376,905 shsMarket Capitalization$217.09 millionP/E RatioN/ADividend YieldN/ABeta0.55 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Veru Inc. operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which is under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil and Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate. The company's oncology drug candidate includes VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-111, an oral alpha and beta tubulin inhibitor, which is under Phase 1b/2 study for the treatment of metastatic prostate, breast, endometrial, ovarian, and pancreatic cancers. It serves agencies, health care distributors, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingVeru has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Veru has a potential upside of 140.2% from its current price of $3.33.Amount of Analyst CoverageVeru has only been the subject of 1 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesVeru has received 226 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVeru has received 169 “underperform” votes. (Add your “underperform” vote.)Community SentimentVeru has received 57.22% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Veru and other stocks. Vote “Outperform” if you believe VERU will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VERU will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVeru does not currently pay a dividend.Dividend GrowthVeru does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veru insiders have bought more of their company's stock than they have sold. Specifically, they have bought $25,690.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 26.10% of the stock of Veru is held by insiders.Percentage Held by InstitutionsOnly 13.58% of the stock of Veru is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Veru are expected to decrease by -38.10% in the coming year, from ($0.21) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veru is -16.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veru is -16.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeru has a P/B Ratio of 6.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.88 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Fabricated rubber products, not elsewhere classified Sub-IndustryPersonal Products SectorMedical Current SymbolNASDAQ:VERU Previous Symbol CUSIP31446210 CIK863894 Webhttp://www.veruhealthcare.com/ Phone305-509-6897Debt Debt-to-Equity Ratio0.06 Current Ratio0.99 Quick Ratio0.72Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$31.80 million Price / Sales6.83 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book6.66Profitability EPS (Most Recent Fiscal Year)($0.19) Net Income$-12,020,000.00 Net Margins-36.58% Return on Equity-40.45% Return on Assets-24.74%Miscellaneous Employees171 Outstanding Shares65,193,000Market Cap$217.09 million Next Earnings Date5/20/2020 (Estimated) OptionableOptionable Receive VERU News and Ratings via Email Sign-up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:VERU Rates by TradingView Veru (NASDAQ:VERU) Frequently Asked Questions How has Veru's stock been impacted by COVID-19 (Coronavirus)? Veru's stock was trading at $3.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VERU shares have increased by 4.1% and is now trading at $3.33. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Veru? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Veru. When is Veru's next earnings date? Veru is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Veru. How were Veru's earnings last quarter? Veru Inc (NASDAQ:VERU) posted its quarterly earnings data on Wednesday, February, 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.02) by $0.03. The firm had revenue of $10.58 million for the quarter, compared to analysts' expectations of $9.30 million. Veru had a negative net margin of 36.58% and a negative return on equity of 40.45%. View Veru's earnings history. What price target have analysts set for VERU? 3 Wall Street analysts have issued 1-year price objectives for Veru's stock. Their forecasts range from $6.00 to $12.00. On average, they anticipate Veru's stock price to reach $8.00 in the next year. This suggests a possible upside of 140.2% from the stock's current price. View analysts' price targets for Veru. Has Veru been receiving favorable news coverage? Headlines about VERU stock have trended very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Veru earned a news impact score of -3.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutVeru. Are investors shorting Veru? Veru saw a decrease in short interest in March. As of March 13th, there was short interest totaling 365,000 shares, a decrease of 5.2% from the February 27th total of 385,100 shares. Based on an average daily trading volume, of 363,300 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.8% of the company's shares are sold short. View Veru's Current Options Chain. Who are some of Veru's key competitors? Some companies that are related to Veru include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Avon Products (AVP), Prestige Consumer Healthcare (PBH), USANA Health Sciences (USNA), Inter Parfums (IPAR), Nu Skin Enterprises (NUS), Medifast (MED), Revlon (REV) and Nature's Sunshine Products (NATR). What other stocks do shareholders of Veru own? Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Corbus Pharmaceuticals (CRBP), Genocea Biosciences (GNCA), Opko Health (OPK), NovaBay Pharmaceuticals (NBY), Rigel Pharmaceuticals (RIGL), Strongbridge Biopharma (SBBP), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD) and Viking Therapeutics (VKTX). Who are Veru's key executives? Veru's management team includes the following people: Dr. Mitchell S. Steiner M.D., F.A.C.S, Chairman, Pres & CEO (Age 58)Dr. Harry Fisch, Vice Chairman & Chief Corp. Officer (Age 60)Mr. O. B. Parrish, Co-Founder & Director (Age 86)Ms. Michele Greco, CFO, Exec. VP of Fin. & Chief Admin. Officer (Age 60)Dr. K. Gary Barnette Ph.D., Chief Scientific Officer (Age 51) What is Veru's stock symbol? Veru trades on the NASDAQ under the ticker symbol "VERU." How do I buy shares of Veru? Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Veru's stock price today? One share of VERU stock can currently be purchased for approximately $3.33. How big of a company is Veru? Veru has a market capitalization of $217.09 million and generates $31.80 million in revenue each year. The company earns $-12,020,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Veru employs 171 workers across the globe. View additional information about Veru. What is Veru's official website? The official website for Veru is http://www.veruhealthcare.com/. How can I contact Veru? Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The company can be reached via phone at 305-509-6897 or via email at [email protected] This page was last updated on 4/10/2020 by MarketBeat.com StaffFeatured Article: Why do commodities matter?
